Search company, investor...
Stemcentrx company logo

Stemcentrx

stemcentrx.com

Stage

Acquired | Acquired

Total Raised

$520M

Valuation

$0000 

About Stemcentrx

Stemcentrx is developing novel cancer therapies and diagnostics. Stemcentrx is looking to treat cancers by killing cancer stem cells, or cells thought to initiate tumors. These cells are believed to resist standard cancer treatments and enable tumors to spread throughout the body.

Headquarters Location

450 East Jamie Court 3rd Floor

South San Francisco, California, 94080,

United States

650-491-0120

Missing: Stemcentrx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stemcentrx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Stemcentrx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Stemcentrx in 1 CB Insights research brief, most recently on Jun 9, 2021.

Expert Collections containing Stemcentrx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stemcentrx is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Stemcentrx Patents

Stemcentrx has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/5/2014

8/21/2018

Monoclonal antibodies, Experimental cancer drugs, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors

Grant

Application Date

11/5/2014

Grant Date

8/21/2018

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Immunology, Clusters of differentiation, Monoclonal antibodies for tumors

Status

Grant

Latest Stemcentrx News

Boulder-based oncology company Enliven Therapeutics raises $55M Series A

Dec 8, 2020

However, the company has not specified what exact types of cancers it’s seeking to address outside of targeting cancers with “suboptimal drugs,” or published its pipeline of drug candidates. A representative declined to specify more details when reached by BizWest, and Enliven has yet to report its fundraising to the U.S. Securities and Exchange Commission as of Tuesday morning. CEO Sam Kintz and Chief Operating Officer Anish Patel both previously worked at Stemcentrx, a San Francisco-based lung-cancer-drug developer that was acquired by AbbVie Inc. (NYSE: ABBV) in 2016 for $5.8 billion in cash and stock. Stemcentrx’s lung-cancer drug failed to pass Phase III trials last August, and AbbVie later took a $4 billion impairment charge on the acquisition. BOULDER — Enliven Therapeutics Inc., a Boulder-based cancer-drug developer, is exiting from stealth operations by announcing that it raised $55 million in its first funding round. The Series A round includes an unspecified investment from the venture-capital arm of Swiss health-care company Roche Holding AG, the company said in a statement. Life science-focused venture-capital firms Orbimed Advisors LLC and 5AM Venture Management LLC also contributed to the round. Sponsored Content

Stemcentrx Frequently Asked Questions (FAQ)

  • Where is Stemcentrx's headquarters?

    Stemcentrx's headquarters is located at 450 East Jamie Court, South San Francisco.

  • What is Stemcentrx's latest funding round?

    Stemcentrx's latest funding round is Acquired.

  • How much did Stemcentrx raise?

    Stemcentrx raised a total of $520M.

  • Who are the investors of Stemcentrx?

    Investors of Stemcentrx include AbbVie, Elon Musk, Fidelity Investments, Deerfield Management, Artis Ventures and 5 more.

  • Who are Stemcentrx's competitors?

    Competitors of Stemcentrx include OncoMed Pharmaceuticals and 1 more.

Compare Stemcentrx to Competitors

A
Avalon

Avalon discovers and develops drugs for various cancers.

B
BresaGen

NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

P
Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells

Regenetech Logo
Regenetech

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

P
PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

Tizona Therapeutics Logo
Tizona Therapeutics

Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. The company was founded in 2015 and is based in South San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.